Combined Treatment of RFA and Sorafenib on Recurrent HCC (REPEAT)
Radiofrequency Ablation Plus Sorafenib Administration in Early Recurrent Hepatocellular Carcinoma: a Prospective Multicenter Cohort Trial (Repeat) Tumors for BCLC B Stage HCC Undergone Curative Hepatectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400038
- Recruiting
- Institute of hepatobiliary surgery,southwest hospital
-
Contact:
- feng xiaobin, MD
- Phone Number: +86-23-13228683243
- Email: fengxiaobin200708@yahoo.com.cn
-
Principal Investigator:
- feng xiaobin, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- recurrent HCC after curative resection
- without gender restriction
- age between 18 to 75 years
- The liver function showed no worse than Child-Pugh B
- tumor nodes were less than 5cm and no more than 3 nodules
Exclusion Criteria:
- Pregnancy patients
- With extrahepatic tumor or lymphnode metastasis
- Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: RFA+Sorafenib
to treat recurrent HCC both with RFA and Sorafenib
|
combined RFA and Sorafenib to treat recurrent HCC
|
|
Active Comparator: RFA group
To treat recurrent HCC with RFA
|
treat Recurrent HCC with RFA
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
time interval between new lessions emerging after the first HCC recurrence
Time Frame: 3 year
|
3 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
3-year overrall survival
Time Frame: 3 year
|
3 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kuansheng Ma, MD,Ph.D, Southwest Hopstial
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- swhb005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.